Search
Alfuzosin
go.drugbank.com/drugs/DB00346Approved[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.
Terconazole
go.drugbank.com/drugs/DB00251Approved[A178096] Terconazole was initially approved by the FDA in 1987.
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnIt is not FDA-approved but available in Japan marketed as Preglandin.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawn[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[L1118] It was never approved by the FDA.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalPhenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed.
Thioredoxin
go.drugbank.com/drugs/DB11298ApprovedAllergens containing disulfide bonds are inactivated when reduced by thioredoxin. … It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIt is an investigational drug under regulatory review by FDA. … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution